目录肽产品
GLUC-011B
Glucagon-Like Peptide II, human
His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-Arg
His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-Arg
Size：1.0
P1(RMB)：1011
MW：3922.4
One letter sequence：HADGSFSDEMNTILDNLAARDFINWLIQTKITDR
Molecular Formula：C171H266N48O56S1
Description：Intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. Currently GLP-2 is used as a potential therapeutic agent for the human subjects with a broad variety of intestinal diseases characterized by intestinal damage and insufficiency.
Literature Reference：D.J. Drucker, Trends Endocrinol. Metab., 10, 153 (1999);\nD.J. Drucker et al., J. Parenter. Enteral Nutr., 23, 598 (1999)
Cas：[99120-49-7]
P1(RMB)：1011
MW：3922.4
One letter sequence：HADGSFSDEMNTILDNLAARDFINWLIQTKITDR
Molecular Formula：C171H266N48O56S1
Description：Intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. Currently GLP-2 is used as a potential therapeutic agent for the human subjects with a broad variety of intestinal diseases characterized by intestinal damage and insufficiency.
Literature Reference：D.J. Drucker, Trends Endocrinol. Metab., 10, 153 (1999);\nD.J. Drucker et al., J. Parenter. Enteral Nutr., 23, 598 (1999)
Cas：[99120-49-7]
-
ADD杭州市钱塘区12号大街69号
-
TEL0571-86737011
-
E-mailsales@chinesepeptide.com
Copyright © 2024 js3983线路检测生化有限公司 All Rights Reserved.
浙ICP备05051877号-1
业务咨询和客户服务
企业微信公众号
